Evusheld No Longer Authorized for COVID Prevention
Tixagevimab-cilgavimab (Evusheld) lost authorization for use in the U.S. to prevent COVID-19 until further notice, the FDA announced on Thursday. The agency revised the monoclonal antibody cocktail’s emergency use authorization (EUA) to limit its use to only periods when SARS-CoV-2 variants susceptible to it account for at least 9% of COVID-19 cases nationally. “Data show […]
Monoclonal Antibodies May No Longer Be a Match for Emerging COVID Strains
Tixagevimab/cilgavimab (Evusheld) and bebtelovimab are likely ineffective against approximately 60% of currently circulating Omicron variants, creating a big gap in protection, particularly for immunocompromised individuals, researchers from a Harvard Medical School-led consortium said at a briefing on Thursday. This is a “big loss,” said Jacob Lemieux, MD, PhD, of the Massachusetts Consortium on Pathogen Readiness […]